CSL-360
CSL-360 is a chimeric unconjugated IgG1 monoclonal antibody targeting CD123. CSL-360 efficiently prevents the binding of IL-3 to CD123, abolishing IL-3 induced cell proliferation. CSL-360 can be used for acute myeloid leukemia (AML) research[1][2].
Product Specifications
UNSPSC
12352100
Target
Interleukin Related
Related Pathways
Immunology/Inflammation
Field of Research
Cancer
References & Citations
[1]Slade MJ, et al. CD123 bi-specific antibodies in development in AML: What do we know so far? Best Pract Res Clin Haematol. 2020 Dec;33 (4) :101219.|[2]Chichili GR, et al. A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: preclinical activity and safety in nonhuman primates. Sci Transl Med. 2015 May 27;7 (289) :289ra82.
Shipping Conditions
Room temperature
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Isoform
IL-13
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC940669-100 1x 100 µL
P27 / KIP1 (SX53G8), CF594 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC741231-100 1x 100 µL
Eosinophil Peroxidase (AHE-1), CF740 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC880257-500 1x 500 µL
Cytokeratin, HMW (AE-3), CF488A conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC471931-100 1x 100 µL
CD3e (T-Cell Marker) (C3e/1931), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC470965-500 1x 500 µL
MUC1 / CA15-3 / EMA / CD227 (Epithelial Marker) (VU-11D1), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details